Cimavax EGF Price
Health is important to people. There are instances wherein individuals suffer from various diseases, and one of these is cancer. In today's time, most people suffer cancer, and among this is the aspect of lung cancer which made a devastated experience to persons who suffered from this disease.
There is a vaccine particular in United Kingdom (UK) which is being tested to reduce significant growth of tumor and will improve the quality of life of patients. This vaccine is known as CimaVax-EGF.
What Is CimaVax-EGF?
CimaVax-EGF is a therapeutic vaccine against lung cancer. It is the first therapeutic kind produced against lung cancer in history. The vaccine was developed by experts at the Molecular Immunology Center at Havana over a period of twenty-five years.
CimaVax-EGF has obtained support for market availability in Cuba. The vaccine works by targeting the epidermal growth factor (EGF), which plays a role in the proliferation of cancer cells. By stimulating the immune system to produce antibodies against EGF, the vaccine aims to slow tumor growth.
Availability and Pricing
As of the publication date of this article (June 2016), pricing information for CimaVax-EGF varied depending on the country and treatment protocol. The vaccine was available in Cuba and was undergoing clinical trials in other nations, including the United Kingdom. Patients and families interested in CimaVax-EGF were advised to consult directly with authorized medical centers in Cuba or participating trial sites for current pricing and eligibility details.
Because CimaVax-EGF is a therapeutic vaccine rather than a preventive one, it is administered to individuals already diagnosed with non-small cell lung cancer. Treatment regimens and associated costs depend on the stage of disease and the specific healthcare provider.